We keep you informed on all updates within the urologic industry by providing the latest news articles from around the globe about our industry. We update this section every week to stay on top of what is new in urology.

Phase 3 Results for Mirabegron in the Treatment of Overactive Bladder

Phase 3 Results for Mirabegron in the Treatment of Overactive Bladder

Astellas Pharma US, Inc announced the results of a pivotal phase 3 clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB). Patients treated with mirabegron showed significant improvements in key OAB symptoms – urinary incontinence and frequency of micturition compared with placebo. These results were also associated with statistically significant improvements in patient reported outcomes.

Mirabegron is a potent and selective beta-3 adrenoceptor agonist. It activates beta-3 adrenoceptor on the detrusor muscle of the bladder to facilitate filling of the bladder and storage of urine.

For more information call (800) 727-7003 begin_of_the_skype_highlighting              (800) 727-7003      end_of_the_skype_highlighting or visit www.us.astellas.com.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>